- Report
- March 2024
- 198 Pages
Global
From €3242EUR$3,374USD£2,788GBP
€3602EUR$3,749USD£3,097GBP
- Report
- January 2024
- 200 Pages
Global
From €4804EUR$5,000USD£4,131GBP
- Report
- May 2024
- 93 Pages
Global
From €5381EUR$5,600USD£4,627GBP
- Report
- October 2023
- 190 Pages
Global
From €4708EUR$4,900USD£4,048GBP
- Report
- April 2023
- 117 Pages
Global
From €4564EUR$4,750USD£3,924GBP
- Report
- July 2021
- 50 Pages
China
From €2498EUR$2,600USD£2,148GBP
- Report
- March 2024
- 114 Pages
Global
From €3500EUR$3,902USD£3,115GBP
- Report
- July 2023
- 105 Pages
Global
From €3500EUR$3,902USD£3,115GBP
- Report
- May 2024
- 50 Pages
Global
From €2546EUR$2,650USD£2,189GBP
- Report
- May 2024
- 50 Pages
Global
From €2546EUR$2,650USD£2,189GBP
- Report
- May 2024
- 50 Pages
Global
From €2546EUR$2,650USD£2,189GBP
Dihydropyridine is a class of drugs used in the treatment of cardiovascular diseases. These drugs are used to treat hypertension, angina, and congestive heart failure. They work by blocking the action of calcium channels in the heart and blood vessels, which helps to reduce blood pressure and improve blood flow. Dihydropyridine drugs are generally well tolerated and have few side effects.
Dihydropyridine drugs are widely used in the treatment of cardiovascular diseases, and are available in both generic and branded forms. They are available in both oral and intravenous formulations, and are often used in combination with other drugs to treat more severe cases.
The dihydropyridine market is highly competitive, with many companies offering a range of products. Some of the major players in the market include Pfizer, Novartis, Merck, Sanofi, and GlaxoSmithKline. Show Less Read more
